PDF
Abstract
Background: New variants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) continue to drive global epidemics and pose significant health risks. The pathogenicity of these variants evolves under immune pressure and host factors. Understanding these changes is crucial for epidemic control and variant research.
Methods: Human angiotensin-converting enzyme 2(hACE2) transgenic mice were intranasally challenged with the original strain WH-09 and the variants Delta, Beta, and Omicron BA.1, while BALB/c mice were challenged with Omicron subvariants BA.5, BF.7, and XBB.1. To compare the pathogenicity differences among variants, we conducted a comprehensive analysis that included clinical symptom observation, measurement of viral loads in the trachea and lungs, evaluation of pulmonary pathology, analysis of immune cell infiltration, and quantification of cytokine levels.
Results: In hACE2 mice, the Beta variant caused significant weight loss, severe lung inflammation, increased inflammatory and chemotactic factor secretion, greater macrophage and neutrophil infiltration in the lungs, and higher viral loads with prolonged shedding duration. In contrast, BA.1 showed a significant reduction in pathogenicity. The BA.5, BF.7, and XBB.1 variants were less pathogenic than the WH-09, Beta, and Delta variants when infected in BALB/c mice. This was evidenced by reduced weight loss, diminished pulmonary pathology, decreased secretion of inflammatory factors and chemokines, reduced macrophage and neutrophil infiltration, as well as lower viral loads in both the trachea and lungs.
Conclusion: In hACE2 mice, the Omicron variant demonstrated the lowest pathogenicity, while the Beta variant exhibited the highest. Pathogenicity of the Delta variant was comparable to the original WH-09 strain. Among BALB/c mice, Omicron subvariants BA.5, BF.7, and XBB.1 showed no statistically significant differences in virulence.
Keywords
mice model
/
pathogenicity
/
SARS-CoV-2
/
variants
Cite this article
Download citation ▾
Qi Lv, Ming Liu, Feifei Qi, Mingya Liu, Fengdi Li, Ran Deng, Xujian Liang, Yanfeng Xu, Zhiqi Song, Yiwei Yan, Shuyue Li, Guocui Mou, Linlin Bao.
Comparison of the pathogenicity of multiple SARS-CoV-2 variants in mouse models.
Animal Models and Experimental Medicine, 2025, 8(7): 1302-1312 DOI:10.1002/ame2.70029
| [1] |
World Health Organization. COVID-19 dashboard.
|
| [2] |
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet (London, England). 2022; 399(10335): 1618-1624.
|
| [3] |
Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3): 162-177.
|
| [4] |
Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. Nature. 2022; 603(7902): 679-686.
|
| [5] |
Liu Z, Li J, Pei S, et al. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 omicron XBB.1.5 and other mutants. Front Cell Infect Microbiol. 2023; 13: 1297078.
|
| [6] |
Team C-F. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023; 401(10379): 833-842.
|
| [7] |
Ou J, Lan W, Wu X, et al. Tracking SARS-CoV-2 omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduct Target Ther. 2022; 7(1): 138.
|
| [8] |
Chen Q, Huang XY, Liu Y, et al. Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. J Med Virol. 2022; 94(7): 3223-3232.
|
| [9] |
Radvak P, Kwon HJ, Kosikova M, et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat Commun. 2021; 12(1): 6559.
|
| [10] |
Liu X, Mostafavi H, Ng WH, et al. The Delta SARS-CoV-2 variant of concern induces distinct pathogenic patterns of respiratory disease in K18-hACE2 transgenic mice compared to the ancestral strain from Wuhan. MBio. 2022; 13(3): e0068322.
|
| [11] |
Shuai H, Chan JF, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 omicron. Nature. 2022; 603(7902): 693-699.
|
| [12] |
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters. Nature. 2022; 603(7902): 687-692.
|
| [13] |
Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to omicron: disease severity and clinical outcomes of major SARS-CoV-2 variants. J Infect Dis. 2023; 227(3): 344-352.
|
| [14] |
Lin L, Liu Y, Tang X, He D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021; 9: 775224.
|
| [15] |
Khan A, Zia T, Suleman M, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. J Cell Physiol. 2021; 236(10): 7045-7057.
|
| [16] |
Zhang Y, Zhang T, Fang Y, Liu J, Ye Q, Ding L. SARS-CoV-2 spike L452R mutation increases omicron variant fusogenicity and infectivity as well as host glycolysis. Signal Transduct Target Ther. 2022; 7(1): 76.
|
| [17] |
Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike mutation T478K. J Med Virol. 2021; 93(9): 5638-5643.
|
| [18] |
Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022; 602(7896): 300-306.
|
| [19] |
Furusawa Y, Kiso M, Iida S, et al. In SARS-CoV-2 delta variants, spike-P681R and D950N promote membrane fusion, spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. EBioMedicine. 2023; 91: 104561.
|
| [20] |
Chen DY, Chin CV, Kenney D, et al. Spike and nsp6 are key determinants of SARS-CoV-2 omicron BA.1 attenuation. Nature. 2023; 615(7950): 143-150.
|
| [21] |
Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020; 583(7818): 830-833.
|
| [22] |
Tsai JJ, Chiou SS, Chen PC, et al. The epidemiology and phylogenetic trends of omicron subvariants from BA.5 to XBB.1 in Taiwan. J Infect Public Health. 2024; 17(11): 102556.
|
| [23] |
Qu L, Xie C, Qiu M, et al. Characterizing infections in two epidemic waves of SARS-CoV-2 omicron variants: a cohort study in Guangzhou, China. Viruses. 2024; 16(4): 649.
|
| [24] |
Liu Y, Liu J, Plante KS, et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022; 602(7896): 294-299.
|
| [25] |
Niu Z, Zhang Z, Gao X, et al. N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding. Signal Transduct Target Ther. 2021; 6(1): 284.
|
| [26] |
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant. Nature. 2022; 603(7902): 700-705.
|
| [27] |
Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 2022; 185(21): 3992-4007.e16.
|
| [28] |
Mohandas S, Shete A, Kumar A, et al. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters. Front Microbiol. 2023; 14: 1183763.
|
| [29] |
Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants. Nat Commun. 2023; 14(1): 2800.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
